Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The US Food and Drug Administration approved Utebzi, tebipenem pivoxil tablets, for complicated urinary tract infections including pyelonephritis caused by susceptible microorganisms in adults who have limited or no alternative oral treatment options.
FDA describes Utebzi as the first oral carbapenem therapy for this indication. The approval addresses a practical treatment gap because complicated UTIs are more likely to involve drug-resistant bacteria and often require hospital-based intravenous therapy.
The agency says efficacy was evaluated in a global, randomized, double-blind, double-dummy noninferiority trial. In that study, 1,690 hospitalized patients were assigned to oral Utebzi 600 mg every six hours or intravenous imipenem-cilastatin 500 mg every six hours for seven to ten days; 929 patients were included in the intent-to-treat population.
FDA says the composite response of clinical cure and microbiological response showed Utebzi effectiveness comparable to imipenem-cilastatin. The most common side effects listed by FDA include diarrhea, headache, nausea, abdominal pain, increased liver enzymes and Clostridioides difficile infection.
Sourcing note: Approval status, indication, trial design, dose comparison, safety summary and special designations are from FDA. The trial result is a noninferiority finding described by the regulator, not a claim that the oral drug is superior to intravenous carbapenem therapy.
Why It Matters
Oral options can change where and how infections are treated, especially when resistance narrows outpatient choices. A first oral carbapenem may reduce some reliance on intravenous therapy, but stewardship, susceptibility testing and clinician oversight remain central to avoiding misuse.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAAntibioticsComplicated UTICarbapenemAntimicrobial Resistance